Biomarkers, Pathways, and Targeted Therapies®
PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.
Most Popular Right Now
Precision Medicine in Oncology®
Precision Medicine—An Inevitable (Though Challenging) Goal!Andre Goy, MD, writes about implementing precision medicine, which requires a global effort from clinicians, insurance providers, government regulators, and the pharmaceutical industry.
Read more >>>